Gland Pharma Gains as USFDA Completes Pre-Approval Inspection at Visakhapatnam Facility
Gland Pharma’s stock surged on the BSE, following the successful conclusion of a Pre-Approval Inspection (PAI) by the United States Food and Drug Administration (USFDA) at its Visakhapatnam facility. The stock is currently trading at ₹1,616.15, up by ₹20.65 or 1.29%, compared to its previous closing price of ₹1,595.50. Stock Performance Overview Opening Price: ₹1,604.85 … Read more
